1Connolly BS,Lang AE.Pharmacological treatment of Parkinson disease:a review.JAMA,2014,311:1670-1683.
2Li Q,Qian ZM,Arbuthnott GW,et al.Cortical effects of deep brain stimulation:implications for pathogenesis and treatment of Parkinson disease.JAMA Neurol,2014,71:100-103.
3Deuschl G,Schade-Brittinger C,Agid Y.Neurostimulation for Parkinson's disease with early motor complications.N Engl J Med,2013,368:2038.
4Palfi S,Gurruchaga JM,Ralph GS,et al.Long-term safety and tolerability of ProSavin,a lentiviral vector-based gene therapy for Parkinson's disease:a dose escalation,open-label,phase 1/2trial.Lancet,2014,383:1138-1146.
5Kefalopoulou Z,Politis M,Piccini P,et al.Long-term clinical outcome of fetal cell transplantation for Parkinson disease:two case reports.JAMA Neurol,2014,71:83-87.
8Morris R. Developments of a water -maze procedure forstudying spatial learning in the rat [J]. Neurosci Methods,1984,ll(l):47-64.
9Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathologicalstudy of 100 cases [ J ]. J Neurol Neurosurg Psychiatry, 1992,55 (3) :181-184.
10Damier P, Hirseh EC, Agid Y, et al. The substantia nigra of the human brain. I. Nigrosomes and lhe nigral matrix, a compartmental organization based on ealbindin D (28K) immunohistoehemistry [ J ]. Brain, 1999,122 ( Pt8 ) : 1421-1436. DOI: http://dx, doi. org/10. 1093/brain/122.8. 1421.
